ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Effects of Fibrinogen Levels on Thromboelastography-Derived Clot Strength in Pregnant Women With or Without Immune Thrombocytopenia.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesPlatelet-fibrin interactions are critical for hemostasis. Thromboelastography (TEG) assesses these dynamics globally. We investigated the role of fibrinogen on TEG-derived clot strength in pregnant women with and without thrombocytopenia, integrating transcriptomic analysis of public datasets to molecularly corroborate our functional findings.MethodsA retrospective study was conducted on 140 third-trimester pregnancies (70 with normal platelet counts and 70 with thrombocytopenia) enrolled between 2015 and 2020. TEG parameters, platelet indices, and fibrinogen concentrations were analyzed. In parallel, public transcriptomic datasets were reanalyzed to explore coagulation- and fibrinogen-related pathways during pregnancy.ResultsMean platelet volume (MPV), platelet count, fibrinogen, and TEG parameters [R-time, K-time, alpha angle, and maximum amplitude (MA)] differed significantly between groups (p < .05). MA positively correlated with platelet count (r = 0.873, p < .001) and fibrinogen concentration (r = 0.410, p < .01). In thrombocytopenic women, MA correlated with platelet count (r = 0.736, p < .0001), MPV (r = 0.447, p < .01), and fibrinogen (r = 0.361, p < .01). Multivariate regression confirmed platelet count and fibrinogen as independent predictors of MA (p < .05). Transcriptomic analysis further demonstrated upregulation of fibrinogen subunits (FGB, F13A1) and enrichment of coagulation pathways in pregnancy, consistent with the functional TEG findings.ConclusionsElevated fibrinogen is associated with and may compensate for preserved clot strength in late pregnancy, particularly in thrombocytopenia. Our integrative analysis provides functional and molecular insights into a potential compensatory mechanism, which forms a rationale for future research to evaluate the therapeutic utility of fibrinogen supplementation. These hypothesis-generating findings warrant prospective interventional validation before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.